硬脑膜中动脉栓塞治疗硬膜下血肿:EMBOLISE试验的CT/MRI终点
EMBOLISE多中心随机试验纳入400例慢性硬膜下血肿患者(352例纳入分析),评估硬脑膜中动脉栓塞联合手术与单纯手术的影像学终点。预设次要影像终点无显著组间差异,但联合栓塞组90天和180天绝对血肿体积显著更低,混合效应模型显示90天血肿体积多减少约25%。
要点
- 联合MMAE组90天血肿体积20.6 mL vs 单纯手术组28.9 mL(P=0.03),180天19.4 mL vs 31.5 mL(P=0.04)。
- 混合效应模型显示MMAE组90天体积多减少6.9 mL(95%CI:-13.5,-0.40;约25%)。
- 预设次要影像终点(血肿体积、厚度、中线移位变化)组间无显著差异。
核心结论
- 预设次要影像终点无显著组间差异,但联合MMAE组90天和180天绝对血肿体积显著低于单纯手术组,混杂因素校正后混合效应分析提示联合MMAE血肿体积减少更多。
研究设计与样本
- EMBOLISE为多中心随机介入试验,2020年12月至2023年8月在美国39个中心开展,400例入组、352例纳入分析(平均年龄72岁±10.4[SD],256例男性),预设次要影像终点为术后24小时至90天CT和MRI血肿体积、厚度及中线移位变化,事后分析扩展至180天并纳入绝对血肿指标,采用混合效应模型校正混杂因素。
关键影像表现/征象
- 筛查时平均cSDH体积为126 mL,组间无差异。
- 90天联合MMAE组血肿体积20.6 mL vs 单纯手术组28.9 mL(P=0.03)。
- 180天联合MMAE组血肿体积19.4 mL vs 单纯手术组31.5 mL(P=0.04)。
- 预设次要影像终点(血肿体积、厚度、中线移位变化)组间无显著差异证据。
诊断标准与关键数值
- 混合效应模型显示MMAE组90天血肿体积多减少6.9 mL(95%CI:-13.5,-0.40;约25%)。
- 混合效应模型显示MMAE组90天绝对血肿体积低8.4 mL(95%CI:-15.2,-1.6;约30%)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Chronic subdural hematomas (cSDHs) are associated with high recurrence risks following surgical evacuation. The EMBOLISE trial demonstrated that, compared with surgery alone, adjunctive middle meningeal artery embolization (MMAE) significantly reduced reoperation rates. However, given the limitations of the clinical end points of the trial, which may be subject to interrater variability and certain biases, the quantitative imaging metrics need to be evaluated. Purpose To evaluate the prespecified imaging end points of the EMBOLISE trial and assess the long-term resolution of cSDH through quantitative imaging analyses. Materials and Methods EMBOLISE was a multicenter, randomized, interventional trial conducted across 39 U.S. sites between December 2020 and August 2023. Prespecified secondary imaging end points included changes in hematoma volume and thickness and midline shifts from 24 hours to 90 days after the procedure at CT and MRI. The post hoc analyses performed herein extended the assessment to 180 days and included absolute hematoma metrics. Mixed-effects modeling was employed to adjust for confounders. Results Four hundred patients were enrolled in the EMBOLISE study, among whom 352 were included (mean age, 72 years ± 10.4 [SD]; 256 men). The mean cSDH volume was 126 mL at screening, with no intergroup differences. At 90 and 180 days, the MMAE plus surgery group had lower cSDH volumes (20.6 mL vs 28.9 mL [P = .03] and 19.4 mL vs 31.5 mL [P = .04], respectively). Mixed-effects models revealed a 6.9 mL (95% CI: -13.5, -0.40; approximately 25%) greater volume reduction and an 8.4 mL (95% CI: -15.2, -1.6; approximately 30%) lower absolute volume at 90 days in the MMAE group There was no evidence of a difference in the prespecified secondary imaging end points between the groups. Conclusion While the prespecified secondary imaging end points did not significantly differ, the absolute 90- and 180-day hematoma volumes were significantly lower in patients who received MMAE and surgery. Confounder-adjusted mixed-effects analysis indicated a greater reduction in hematoma volume with adjunctive MMAE. ClinicalTrials.gov identifier NCT04402632 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Ramasamy and Baker in this issue.
引用
- Kniep H, Gellissen S, Bechstein M, et al. Middle Meningeal Artery Embolization for Subdural Hematoma: CT/MRI End Points of the EMBOLISE Trial. Radiology. 2026. PMID: 41591252. doi:10.1148/radiol.251746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。